NASDAQ$VIR
Vir Biotechnology Inc · Q2 2025 earnings
Q2 2025 earnings · · After market close · Investor relations
Briefing
Vir Biotechnology Inc reported a net loss of $111 million for the second quarter of 2025 driven by continued investment in clinical programs.
The company recorded total revenues of $1.2 million for the three months ended June 30, 2025, primarily from contract and grant revenue, offset by a negative collaboration revenue adjustment. Operating expenses totaled $120 million, led by research and development costs of $98 million, resulting in a loss from operations of $118 million. The company maintains a strong liquidity position with $211 million in cash and cash equivalents and $892 million in cash, cash equivalents, and investments.
- Net loss of $111 million for Q2 2025 compared to $138 million in Q2 2024, reflecting cost reductions from restructuring.
- R&D expenses decreased to $98 million from $105 million year-over-year due to program prioritization.
- ECLIPSE registrational program for chronic hepatitis delta fully underway with multiple trials initiated.
- First patient dosed in Phase 1 study of VIR-5525, advancing the oncology pipeline with PRO-XTEN masked TCEs.
Headline financials
Revenue & EPS history
Vir · Revenue · Quarterly
$1.21M
Revenue by segment
Vir · $1.21M total across 3 segments · Q2 2025
- Contract revenue$1.53M—125.7%
- Grant revenue$183K—15.1%
- Collaboration revenue-$495K—-40.8%
Forward guidance
The company expects nominal collaboration revenue in 2025 and continues to advance its CHD and oncology clinical programs with ongoing cost management initiatives.
Tailwinds
- Advancement of ECLIPSE program and first patient dosed in VIR-5525 Phase 1 study
- Strong cash position supporting operations through at least 12 months
Headwinds
- Continued net losses expected due to R&D investment
- Limited near-term revenue from COVID-19 related products
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports
+2.0%
Avg return
Earnings day
-0.4%
Avg return
5 days after
-1.3%
Avg return
30 days after
43%
12 / 28 earnings
Positive
+27.7%
Q4 2025
Best reaction
-15.1%
Q3 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2026 | +2.8% | -7.2% | -13.7% | |
| Q4 2025 | +27.7% | +22.3% | +20.6% | |
| Q3 2025 | -5.6% | -8.9% | +8.3% | |
| Q1 2025 | -3.4% | -16.2% | -2.9% | |
| Q4 2024 | -11.8% | -10.9% | -27.2% | |
| Q3 2024 | +21.8% | +26.8% | +4.7% | |
| Q2 2024 | -9.4% | -15.4% | -18.7% | |
| Q1 2024 | +18.9% | +13.6% | +17.5% | |
| Q4 2023 | +14.0% | +13.1% | -0.6% | |
| Q3 2023 | +12.5% | +8.3% | +24.4% | |
| Q2 2023 | -3.0% | -4.8% | -10.9% | |
| Q1 2023 | -3.5% | -4.5% | +7.5% | |
| Q4 2022 | -14.8% | -15.6% | -16.7% | |
| Q3 2022 | +15.0% | +20.3% | +23.7% | |
| Q2 2022 | +2.0% | -4.9% | -25.9% | |
| Q1 2022 | -3.1% | -1.4% | +12.5% | |
| Q4 2021 | +0.1% | -13.7% | -21.5% | |
| Q3 2021 | -15.1% | -11.7% | +20.4% | |
| Q2 2021 | +3.3% | +10.5% | +32.0% | |
| Q1 2021 | -1.0% | -8.5% | +3.5% | |
| Q4 2020 | -4.2% | -11.7% | -21.2% | |
| Q3 2020 | +8.2% | +5.8% | +26.0% | |
| Q2 2020 | -0.6% | -0.9% | -46.8% | |
| Q2 2019 | -0.6% | -0.9% | -46.8% | |
| Q1 2020 | -1.9% | -3.1% | +7.2% | |
| Q1 2019 | -1.9% | -3.1% | +7.2% | |
| Q4 2019 | +11.5% | +11.4% | +6.0% | |
| Q3 2019 | -3.0% | -0.5% | -3.7% | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro